By 2030, it is anticipated that the UK Liver Cancer Therapeutics market will reach a value of $242.9 Mn from $76.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30. Liver Cancer Therapeutics in the UK is dominated by a few domestic pharmaceutical companies such as GlaxoSmithKline, Oxford BioTherapeutics, AstraZeneca, and Jazz Pharmaceuticals. The Liver Cancer Therapeutics market in the UK is segmented into different types of cancer and different therapy types. Some of the major factors affecting the UK Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the UK Liver Cancer Therapeutics market will reach a value of $242.9 Mn from $76.2 Mn in 2022, growing at a CAGR of 15.6% during 2022-30.
The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. According to the most recent WHO data, 5,237 people died from liver cancer in the United Kingdom in 2020, accounting for 1.02 % of all deaths. The age-adjusted death rate of 3.64 per 100,000 inhabitants ranks the United Kingdom 146th in the world.
According to a World Health Organization (WHO) country profile health report, a few adult risk factors responsible for the rise in common diseases in the United Kingdom include cigarette use, alcohol use, high blood pressure, and obesity. In the United Kingdom, the usage of liver cancer therapies is determined by the stage and severity of the cancer, as well as the patient's overall condition. UK's government spends 12 % of its GDP on healthcare.
Market Growth Drivers Analysis
The prevalence of liver cancer is increasing in the United Kingdom. According to the International Agency for Research on Cancer, the predicted number of new cancer cases in the UK due to alcohol consumption in 2020 was 1400. Pharmaceuticals are one of the UK's cutting-edge industries. Several variables have been associated with an increased risk of liver cancer, including older age, HIV or Aids, a family history of the disease, and ethnicity, with black and Asian persons being more likely to develop the disease. These aspects could boost the UK Liver Cancer Therapeutics market.
Market Restraints
The UK's low productivity and lack of training are not conducive to innovation. Adherence to regulatory guidelines established by organizations such as the UK's Medicines and Healthcare Products Regulatory Agency is required while developing new drugs and therapies (MHRA). These criteria can be complex and time-consuming, leading to delays and increased costs. These factors may deter new entrants into the UK Liver Cancer Therapeutics market.
Key Players
February 2023: Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations from AstraZeneca have been approved for the treatment of advanced liver and lung malignancies in the European Union (EU). The two European Commission approvals follow positive recommendations by the European Medicines Agency's Committee for Medicinal Products for Human Use in December 2022 and are based on positive results from the HIMALAYA Phase III trial, published in the New England Journal of Medicine Evidence, and the POSEIDON Phase III trial, published in the Journal of Clinical Oncology.
April 2022: A new treatment for liver cancer that isolates the organ while protecting other areas of the body has been shown to be effective in nearly 90% of patients. The method, which is being developed at University Hospital Southampton in the United Kingdom, involves using two small balloons to reroute blood through the liver for an hour while delivering medications straight into the organ.
In the UK, the regulation and reimbursement of liver cancer therapeutics are overseen by several entities, including the Medicines and Healthcare Products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE). The reimbursement process for liver cancer therapeutics in the UK is largely determined by the National Health Service (NHS), which is responsible for providing healthcare services to residents of the UK.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
By Treatment (Revenue, USD Billion):
By Equipment (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
In the UK, the regulation and reimbursement of liver cancer therapeutics is overseen by several entities, including the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).
The reimbursement process for liver cancer therapeutics in the UK is largely determined by the National Health Service (NHS), which is responsible for providing healthcare services to residents of the UK.
Liver Cancer Therapeutics in the UK is dominated by a few domestic pharmaceutical companies such as GlaxoSmithKline, Oxford BioTherapeutics, AstraZeneca and Jazz Pharmaceuticals.